Most Read Articles
4 days ago
The use of capsule endoscopy (CE) appears to be effective in the diagnosis of iron deficiency anaemia (IDA), yielding a 33.9-percent yield in this study, with 65.8 percent of patients undergoing further workup and 12.7 percent requiring therapeutic intervention.
Tristan Manalac, 3 days ago
Minimally invasive pancreatectomy (MIP) offers a feasible alternative to open pancreatectomy (OP) for the treatment of pancreatic neuroendocrine neoplasms (PNEN), according to a recent Singapore study has found.
Yesterday
The perception that proton pump inhibitors (PPIs) cause multiple serious adverse effects (AEs) is supported by many internists, who then recommend treatment cessation even in patients at high risk for upper gastrointestinal bleeding (UGIB), reveals a study.
21 May 2020
At the 13th Annual Scientific Meeting of the Malaysian Osteoporosis Society (MOS), Dr Chan Siew Pheng discussed the role of alfacalcidol (One-Alpha®) in the treatment of osteoporosis (OP) and presented several patient profiles where alfacalcidol exhibited efficacy in increasing bone mineral density (BMD).

Lenabasum for diffuse cutaneous systemic sclerosis aces phase II trial

6 days ago

Treatment with lenabasum is safe and helps improve outcomes in patients with diffuse cutaneous systemic sclerosis (dcSSc), according to the results of a phase II study.

The study randomized adult patients with dcSSc for ≤6 years and on stable standard‐of‐care treatment to receive either lenabasum (n=27) or placebo (n=15). The study drug was given at 5 mg once daily (QD), 20 mg QD or 20 mg twice daily (BID) for 4 weeks, then 20 mg BID for 8 weeks. Researchers conducted safety and efficacy assessments at weeks 4, 8, 12 and 16.

Active treatment led to a more favourable improvement in American College of Rheumatology Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score, which reached 0.33 vs 0.00 with placebo at week 16 (p=0.07). Lenabasum also produced greater improvements in other efficacy outcomes that assessed overall disease, skin involvement and patient‐reported function.

Gene expression in inflammation and fibrosis pathways decreased more with the study drug vs placebo, with significant improvements in inflammation and fibrosis by histological evaluation of skin biopsies (p≤0.05).

Adverse events (AEs) occurred in 63 percent of patients in the lenabasum group and in 60 percent of the placebo group. Commonly reported AEs were dizziness (22 percent vs 13 percent), fatigue (19 percent vs 7 percent), headache (11 percent vs 7 percent), arthralgia (11 percent vs 7 percent), upper respiratory tract infection (11 percent vs 0 percent), nausea (4 percent vs 13 percent) and decreased forced vital capacity (0 percent vs 13 percent). There were no serious AEs related to active treatment.

Despite a short trial duration and a small number of patients, the findings are encouraging and support the therapeutic potential of lenabasum in dcSSc, the researchers said, adding that further evaluation of the drug is warranted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
The use of capsule endoscopy (CE) appears to be effective in the diagnosis of iron deficiency anaemia (IDA), yielding a 33.9-percent yield in this study, with 65.8 percent of patients undergoing further workup and 12.7 percent requiring therapeutic intervention.
Tristan Manalac, 3 days ago
Minimally invasive pancreatectomy (MIP) offers a feasible alternative to open pancreatectomy (OP) for the treatment of pancreatic neuroendocrine neoplasms (PNEN), according to a recent Singapore study has found.
Yesterday
The perception that proton pump inhibitors (PPIs) cause multiple serious adverse effects (AEs) is supported by many internists, who then recommend treatment cessation even in patients at high risk for upper gastrointestinal bleeding (UGIB), reveals a study.
21 May 2020
At the 13th Annual Scientific Meeting of the Malaysian Osteoporosis Society (MOS), Dr Chan Siew Pheng discussed the role of alfacalcidol (One-Alpha®) in the treatment of osteoporosis (OP) and presented several patient profiles where alfacalcidol exhibited efficacy in increasing bone mineral density (BMD).